HBM gets health boost from drug licensing deals December 22, 2023 2142.HK 1.56 (-2.5%) The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion HBM Holdin...
Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems. Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up.$康希諾生物(06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million.$瑞科生物-B(02179.HK)$,$諾誠健華(09969.HK)$and ...
和鉑醫藥-B股票討論區
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...
Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up. $康希諾生物(06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million. $瑞科生物-B(02179.HK)$ , $諾誠健華(09969.HK)$ and ...
暫無評論